GSK2245035

GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN) -stimulating properties. GSK2245035 has pEC50s of 9.3 and 6.5 for IFNα and TFNα. GSK2245035 effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 is used for asthma[1].

Product Specifications

CAS Number

[1207629-49-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335, H361

Target

IFNAR; TNF Receptor; Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/gsk2245035.html

Purity

99.79

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C1NC2=C(N=C(N=C2N1CCCCCN3CCCCC3)O[C@H](CCC)C)N

Molecular Formula

C20H34N6O2

Molecular Weight

390.52

Precautions

H302, H315, H319, H335, H361

References & Citations

[1]Biggadike K, et al. Discovery of 6-Amino-2-{[ (1S) -1-methylbutyl]oxy}-9-[5- (1-piperidinyl) pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma. J Med Chem. 2016 Mar 10;59 (5) :1711-26.